NPR-B Inhibitors
1 drugsAbout NPR-B
NPR-B (Natriuretic Peptide Receptor B) is a cell-surface receptor that binds natriuretic peptides, regulating fluid and electrolyte balance. It plays a key role in cardiovascular homeostasis and blood pressure control through downstream signaling pathways.
Currently, there is no genetic evidence directly linking NPR-B to specific diseases, limiting confidence in target validation. However, its role in physiological processes suggests potential for therapeutic intervention in related disorders.
NPR-B is targeted by one FDA-approved drug, VOXZOGO (lonapegsomatropin), a peptide therapy developed by BIOMARIN PHARM. This single drug highlights the feasibility of targeting NPR-B, though further exploration is needed.
Top NPR-B Drugs
BIOMARIN PHARM is the only company with an approved drug targeting NPR-B.
The lack of competitors indicates a high-risk, high-reward opportunity, but also potential barriers to entry or limited market demand.
NPR-B Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets NPR-B, using peptide modality.
Explore alternative modalities like small molecules or antibodies to differentiate from existing peptide therapies and expand market reach.
NPR-B Clinical Trials 10 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on NPR-B. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 1 | 0 | 0 | 1 | - |
| Phase 2 | 7 | 0 | 0 | 7 | - |
| Phase 3 | 2 | 0 | 0 | 2 | - |
Top Sponsors
By Modality
Top Conditions
Top Drugs
NPR-B Drug Approval Timeline (2021 - 2021)
The first and only drug, VOXZOGO, was approved in 2021.
Recent approval suggests growing interest, but limited history indicates uncertainty; monitor market response before investing heavily.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 4 (1 company)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on NPR-B. A trial counts if an approved drug acting on NPR-B is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.